+357 96 030922
info@marketpublishers.com

Global Obesity-Diabetes Drug Market Research Report 2026(Status and Outlook)

https://marketpublishers.com/r/GD26A3AC22C9EN.html
Date: May 2026
Pages: 136
Price: US$ 3,200.00 (Single User License)
ID: GD26A3AC22C9EN

Abstracts

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Obesity-Diabetes Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Obesity-Diabetes Drugs are a class of therapeutic agents designed for the integrated management of obesity and type 2 diabetes mellitus. These drugs act through multiple pathways—improving insulin sensitivity, regulating energy metabolism, and modulating appetite control—to achieve dual effects on weight reduction and glycemic control. Key mechanisms include GLP-1 receptor agonists, GIP/GLP-1 dual agonists, insulin secretagogues, and novel lipid metabolism modulators. With the growing prevalence of obesity-diabetes comorbidity, the boundary between anti-obesity and antidiabetic medications is increasingly blurred, leading to a trend toward “metabolic-integrated” therapies. Beyond blood glucose and weight control, these drugs also reduce cardiovascular risk, improve hepatic lipid metabolism, and alleviate systemic inflammation, positioning them as one of the most promising directions in global metabolic disease treatment.In 2024, global Obesity-Diabetes Drug production reached approximately 118.68 million units, with an average global market price of around US$ 500 perunit.The average gross profit margin of this product is 75%.The global co-prevalence of obesity and type 2 diabetes continues to drive rapid market expansion for obesity-diabetes drugs. Aging populations, sedentary lifestyles, and widespread high-calorie diets have caused a surge in metabolic syndrome cases, creating a vast potential patient pool. The new generation of GLP-1 and dual agonist drugs demonstrates superior weight loss and glycemic control outcomes, improving both patient compliance and physician prescription rates. Growing emphasis on chronic disease management across healthcare systems has expanded reimbursement coverage through public and private insurance. Meanwhile, collaboration between major

+357 96 030922
info@marketpublishers.com

pharmaceutical companies and biotech firms is accelerating innovation pipelines and clinical adoption, fueling sustainable market growth.Despite strong growth potential, the obesity-diabetes drug market faces significant challenges. Drug development is costly and lengthy, with stringent regulatory requirements for long-term efficacy and safety. Some GLP-1 class drugs cause gastrointestinal side effects, reducing long-term adherence. High prices and limited insurance reimbursement restrict accessibility in low- and middle-income countries. Competition is intensifying as major players like Novo Nordisk and Eli Lilly have established strong brand and technology barriers, creating high entry thresholds for newcomers. Furthermore, limited patient awareness and the need for long-term clinical outcome validation add uncertainty to the market outlook.Downstream demand is shifting toward diversification and integration. Hospitals and metabolic clinics are transitioning from glucose-centric therapy to comprehensive weight and metabolic management, driving rapid adoption of GLP-1 and GIP/GLP-1 dual agonists. Rising attention to early-stage metabolic disorders and mild obesity among consumers is fostering a preventive and lifestyle-integrated approach. The integration of digital health platforms and remote monitoring tools enables personalized medication management. Pharmaceutical companies are also collaborating with nutrition, fitness, and wearable technology firms to expand their product ecosystems and meet holistic healthcare needs spanning from clinical treatment to preventive wellness.The upstream supply chain of obesity-diabetes drugs mainly consists of peptide synthesis materials, formulation excipients, and components for injectable delivery systems. GLP-1 drugs rely on peptide-based active ingredients requiring high-purity amino acids and advanced solid-phase synthesis technologies, with strict aseptic and purification standards. Delivery carriers such as liposomes, sustained-release microspheres, and PEGylation materials determine the pharmacokinetic profile and stability of the final drug. Injection pens and prefilled syringes play key roles in patient experience and product acceptance. However, fluctuations in raw material prices, patent monopolies, and limited availability of specialized manufacturing equipment pose potential bottlenecks in the upstream supply chain.

The global Obesity-Diabetes Drug market size was estimated at USD 59341.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.50% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Obesity-Diabetes Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts

+357 96 030922
info@marketpublishers.com

SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Obesity-Diabetes Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Obesity-Diabetes Drug market.

Global Obesity-Diabetes Drug Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Novo Nordisk

Eli Lilly

Boehringer Ingelheim

+357 96 030922
info@marketpublishers.com

Sanofi

Vertex Pharmaceuticals

AstraZeneca

MannKind Corporation

BENEMAE

Xeris Pharmaceuticals

Market Segmentation (by Type)

GLP-1 Receptor Agonists

Insulin Secretagogues

Other

Market Segmentation (by Application)

Hospital

Clinic

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

+357 96 030922
info@marketpublishers.com

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Obesity-Diabetes Drug Market

Overview of the regional outlook of the Obesity-Diabetes Drug Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

+357 96 030922
info@marketpublishers.com

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Obesity-Diabetes Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Obesity-Diabetes Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

+357 96 030922
info@marketpublishers.com

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

+357 96 030922
info@marketpublishers.com

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

+357 96 030922
info@marketpublishers.com

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Obesity-Diabetes Drug
1.2 Key Market Segments
  1.2.1 Obesity-Diabetes Drug Segment by Type
  1.2.2 Obesity-Diabetes Drug Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 OBESITY-DIABETES DRUG MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Obesity-Diabetes Drug Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Obesity-Diabetes Drug Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 OBESITY-DIABETES DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Obesity-Diabetes Drug Product Life Cycle
3.3 Global Obesity-Diabetes Drug Sales by Manufacturers (2020-2025)
3.4 Global Obesity-Diabetes Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Obesity-Diabetes Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Obesity-Diabetes Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers' Manufacturing Sites, Areas Served, and Product Types
3.8 Obesity-Diabetes Drug Market Competitive Situation and Trends
  3.8.1 Obesity-Diabetes Drug Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Obesity-Diabetes Drug Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

+357 96 030922
info@marketpublishers.com

4 OBESITY-DIABETES DRUG INDUSTRY CHAIN ANALYSIS

4.1 Obesity-Diabetes Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF OBESITY-DIABETES DRUG MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Obesity-Diabetes Drug Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Obesity-Diabetes Drug Market
5.7 ESG Ratings of Leading Companies

6 OBESITY-DIABETES DRUG MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Obesity-Diabetes Drug Sales Market Share by Type (2020-2025)
6.3 Global Obesity-Diabetes Drug Market Size by Type (2020-2025)
6.4 Global Obesity-Diabetes Drug Price by Type (2020-2025)

7 OBESITY-DIABETES DRUG MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

+357 96 030922
info@marketpublishers.com

7.2 Global Obesity-Diabetes Drug Market Sales by Application (2020-2025)
7.3 Global Obesity-Diabetes Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Obesity-Diabetes Drug Sales Growth Rate by Application (2020-2025)

8 OBESITY-DIABETES DRUG MARKET SALES BY REGION

8.1 Global Obesity-Diabetes Drug Sales by Region
  8.1.1 Global Obesity-Diabetes Drug Sales by Region
  8.1.2 Global Obesity-Diabetes Drug Sales Market Share by Region
8.2 Global Obesity-Diabetes Drug Market Size by Region
  8.2.1 Global Obesity-Diabetes Drug Market Size by Region
  8.2.2 Global Obesity-Diabetes Drug Market Size by Region
8.3 North America
  8.3.1 North America Obesity-Diabetes Drug Sales by Country
  8.3.2 North America Obesity-Diabetes Drug Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Obesity-Diabetes Drug Sales by Country
  8.4.2 Europe Obesity-Diabetes Drug Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Obesity-Diabetes Drug Sales by Region
  8.5.2 Asia Pacific Obesity-Diabetes Drug Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Obesity-Diabetes Drug Sales by Country
  8.6.2 South America Obesity-Diabetes Drug Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview

+357 96 030922
info@marketpublishers.com

8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Obesity-Diabetes Drug Sales by Region
8.7.2 Middle East and Africa Obesity-Diabetes Drug Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview

9 OBESITY-DIABETES DRUG MARKET PRODUCTION BY REGION

9.1 Global Production of Obesity-Diabetes Drug by Region(2020-2025)
9.2 Global Obesity-Diabetes Drug Revenue Market Share by Region (2020-2025)
9.3 Global Obesity-Diabetes Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Obesity-Diabetes Drug Production
9.4.1 North America Obesity-Diabetes Drug Production Growth Rate (2020-2025)
9.4.2 North America Obesity-Diabetes Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Obesity-Diabetes Drug Production
9.5.1 Europe Obesity-Diabetes Drug Production Growth Rate (2020-2025)
9.5.2 Europe Obesity-Diabetes Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Obesity-Diabetes Drug Production (2020-2025)
9.6.1 Japan Obesity-Diabetes Drug Production Growth Rate (2020-2025)
9.6.2 Japan Obesity-Diabetes Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Obesity-Diabetes Drug Production (2020-2025)
9.7.1 China Obesity-Diabetes Drug Production Growth Rate (2020-2025)
9.7.2 China Obesity-Diabetes Drug Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Novo Nordisk
10.1.1 Novo Nordisk Basic Information
10.1.2 Novo Nordisk Obesity-Diabetes Drug Product Overview
10.1.3 Novo Nordisk Obesity-Diabetes Drug Product Market Performance

+357 96 030922
info@marketpublishers.com

10.1.4 Novo Nordisk Business Overview
10.1.5 Novo Nordisk SWOT Analysis
10.1.6 Novo Nordisk Recent Developments
10.2 Eli Lilly
10.2.1 Eli Lilly Basic Information
10.2.2 Eli Lilly Obesity-Diabetes Drug Product Overview
10.2.3 Eli Lilly Obesity-Diabetes Drug Product Market Performance
10.2.4 Eli Lilly Business Overview
10.2.5 Eli Lilly SWOT Analysis
10.2.6 Eli Lilly Recent Developments
10.3 Boehringer Ingelheim
10.3.1 Boehringer Ingelheim Basic Information
10.3.2 Boehringer Ingelheim Obesity-Diabetes Drug Product Overview
10.3.3 Boehringer Ingelheim Obesity-Diabetes Drug Product Market Performance
10.3.4 Boehringer Ingelheim Business Overview
10.3.5 Boehringer Ingelheim SWOT Analysis
10.3.6 Boehringer Ingelheim Recent Developments
10.4 Sanofi
10.4.1 Sanofi Basic Information
10.4.2 Sanofi Obesity-Diabetes Drug Product Overview
10.4.3 Sanofi Obesity-Diabetes Drug Product Market Performance
10.4.4 Sanofi Business Overview
10.4.5 Sanofi Recent Developments
10.5 Vertex Pharmaceuticals
10.5.1 Vertex Pharmaceuticals Basic Information
10.5.2 Vertex Pharmaceuticals Obesity-Diabetes Drug Product Overview
10.5.3 Vertex Pharmaceuticals Obesity-Diabetes Drug Product Market Performance
10.5.4 Vertex Pharmaceuticals Business Overview
10.5.5 Vertex Pharmaceuticals Recent Developments
10.6 AstraZeneca
10.6.1 AstraZeneca Basic Information
10.6.2 AstraZeneca Obesity-Diabetes Drug Product Overview
10.6.3 AstraZeneca Obesity-Diabetes Drug Product Market Performance
10.6.4 AstraZeneca Business Overview
10.6.5 AstraZeneca Recent Developments
10.7 MannKind Corporation
10.7.1 MannKind Corporation Basic Information
10.7.2 MannKind Corporation Obesity-Diabetes Drug Product Overview
10.7.3 MannKind Corporation Obesity-Diabetes Drug Product Market Performance

+357 96 030922
info@marketpublishers.com

10.7.4 MannKind Corporation Business Overview
10.7.5 MannKind Corporation Recent Developments
10.8 BENEMAE
10.8.1 BENEMAE Basic Information
10.8.2 BENEMAE Obesity-Diabetes Drug Product Overview
10.8.3 BENEMAE Obesity-Diabetes Drug Product Market Performance
10.8.4 BENEMAE Business Overview
10.8.5 BENEMAE Recent Developments
10.9 Xeris Pharmaceuticals
10.9.1 Xeris Pharmaceuticals Basic Information
10.9.2 Xeris Pharmaceuticals Obesity-Diabetes Drug Product Overview
10.9.3 Xeris Pharmaceuticals Obesity-Diabetes Drug Product Market Performance
10.9.4 Xeris Pharmaceuticals Business Overview
10.9.5 Xeris Pharmaceuticals Recent Developments

11 OBESITY-DIABETES DRUG MARKET FORECAST BY REGION

11.1 Global Obesity-Diabetes Drug Market Size Forecast
11.2 Global Obesity-Diabetes Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Obesity-Diabetes Drug Market Size Forecast by Country
11.2.3 Asia Pacific Obesity-Diabetes Drug Market Size Forecast by Region
11.2.4 South America Obesity-Diabetes Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Obesity-Diabetes Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Obesity-Diabetes Drug Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Obesity-Diabetes Drug by Type (2026-2035)
12.1.2 Global Obesity-Diabetes Drug Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Obesity-Diabetes Drug by Type (2026-2035)
12.2 Global Obesity-Diabetes Drug Market Forecast by Application (2026-2035)
12.2.1 Global Obesity-Diabetes Drug Sales (K MT) Forecast by Application
12.2.2 Global Obesity-Diabetes Drug Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Obesity-Diabetes Drug Market Size by Type (M USD)
Table 4. Global Obesity-Diabetes Drug Market Size by Application
Table 5. Obesity-Diabetes Drug Market Size Comparison by Region (M USD)
Table 6. Global Obesity-Diabetes Drug Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Obesity-Diabetes Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Obesity-Diabetes Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Obesity-Diabetes Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Obesity-Diabetes Drug as of 2025)
Table 11. Global Market Obesity-Diabetes Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Obesity-Diabetes Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Obesity-Diabetes Drug Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Obesity-Diabetes Drug Sales by Type (K MT)
Table 27. Global Obesity-Diabetes Drug Market Size by Type (M USD)
Table 28. Global Obesity-Diabetes Drug Sales (K MT) by Type (2020-2025)
Table 29. Global Obesity-Diabetes Drug Sales Market Share by Type (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 30. Global Obesity-Diabetes Drug Market Size (M USD) by Type (2020-2025)
Table 31. Global Obesity-Diabetes Drug Market Share by Type (2020-2025)
Table 32. Global Obesity-Diabetes Drug Price (USD/KG) by Type (2020-2025)
Table 33. Global Obesity-Diabetes Drug Sales (K MT) by Application
Table 34. Global Obesity-Diabetes Drug Market Size by Application
Table 35. Global Obesity-Diabetes Drug Sales by Application (2020-2025) & (K MT)
Table 36. Global Obesity-Diabetes Drug Sales Market Share by Application (2020-2025)
Table 37. Global Obesity-Diabetes Drug Market Size by Application (2020-2025) & (M USD)
Table 38. Global Obesity-Diabetes Drug Market Share by Application (2020-2025)
Table 39. Global Obesity-Diabetes Drug Sales Growth Rate by Application (2020-2025)
Table 40. Global Obesity-Diabetes Drug Sales by Region (2020-2025) & (K MT)
Table 41. Global Obesity-Diabetes Drug Sales Market Share by Region (2020-2025)
Table 42. Global Obesity-Diabetes Drug Market Size by Region (2020-2025) & (M USD)
Table 43. Global Obesity-Diabetes Drug Market Size by Region (2020-2025)
Table 44. North America Obesity-Diabetes Drug Sales by Country (2020-2025) & (K MT)
Table 45. North America Obesity-Diabetes Drug Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Obesity-Diabetes Drug Sales by Country (2020-2025) & (K MT)
Table 47. Europe Obesity-Diabetes Drug Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Obesity-Diabetes Drug Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Obesity-Diabetes Drug Market Size by Region (2020-2025) & (M USD)
Table 50. South America Obesity-Diabetes Drug Sales by Country (2020-2025) & (K MT)
Table 51. South America Obesity-Diabetes Drug Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Obesity-Diabetes Drug Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Obesity-Diabetes Drug Market Size by Region (2020-2025) & (M USD)
Table 54. Global Obesity-Diabetes Drug Production (K MT) by Region(2020-2025)
Table 55. Global Obesity-Diabetes Drug Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Obesity-Diabetes Drug Revenue Market Share by Region (2020-2025)
Table 57. Global Obesity-Diabetes Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 58. North America Obesity-Diabetes Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Obesity-Diabetes Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Obesity-Diabetes Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Obesity-Diabetes Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Novo Nordisk Basic Information
Table 63. Novo Nordisk Obesity-Diabetes Drug Product Overview
Table 64. Novo Nordisk Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Novo Nordisk Business Overview
Table 66. Novo Nordisk SWOT Analysis
Table 67. Novo Nordisk Recent Developments
Table 68. Eli Lilly Basic Information
Table 69. Eli Lilly Obesity-Diabetes Drug Product Overview
Table 70. Eli Lilly Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Eli Lilly Business Overview
Table 72. Eli Lilly SWOT Analysis
Table 73. Eli Lilly Recent Developments
Table 74. Boehringer Ingelheim Basic Information
Table 75. Boehringer Ingelheim Obesity-Diabetes Drug Product Overview
Table 76. Boehringer Ingelheim Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Boehringer Ingelheim Business Overview
Table 78. Boehringer Ingelheim SWOT Analysis
Table 79. Boehringer Ingelheim Recent Developments
Table 80. Sanofi Basic Information
Table 81. Sanofi Obesity-Diabetes Drug Product Overview
Table 82. Sanofi Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Sanofi Business Overview
Table 84. Sanofi Recent Developments
Table 85. Vertex Pharmaceuticals Basic Information
Table 86. Vertex Pharmaceuticals Obesity-Diabetes Drug Product Overview
Table 87. Vertex Pharmaceuticals Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 88. Vertex Pharmaceuticals Business Overview
Table 89. Vertex Pharmaceuticals Recent Developments
Table 90. AstraZeneca Basic Information
Table 91. AstraZeneca Obesity-Diabetes Drug Product Overview
Table 92. AstraZeneca Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. AstraZeneca Business Overview
Table 94. AstraZeneca Recent Developments
Table 95. MannKind Corporation Basic Information
Table 96. MannKind Corporation Obesity-Diabetes Drug Product Overview
Table 97. MannKind Corporation Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. MannKind Corporation Business Overview
Table 99. MannKind Corporation Recent Developments
Table 100. BENEMAE Basic Information
Table 101. BENEMAE Obesity-Diabetes Drug Product Overview
Table 102. BENEMAE Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. BENEMAE Business Overview
Table 104. BENEMAE Recent Developments
Table 105. Xeris Pharmaceuticals Basic Information
Table 106. Xeris Pharmaceuticals Obesity-Diabetes Drug Product Overview
Table 107. Xeris Pharmaceuticals Obesity-Diabetes Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Xeris Pharmaceuticals Business Overview
Table 109. Xeris Pharmaceuticals Recent Developments
Table 110. Global Obesity-Diabetes Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 111. Global Obesity-Diabetes Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 112. North America Obesity-Diabetes Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 113. North America Obesity-Diabetes Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 114. Europe Obesity-Diabetes Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 115. Europe Obesity-Diabetes Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 116. Asia Pacific Obesity-Diabetes Drug Sales Forecast by Region (2026-2035) &

+357 96 030922
info@marketpublishers.com

(K MT)
Table 117. Asia Pacific Obesity-Diabetes Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 118. South America Obesity-Diabetes Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 119. South America Obesity-Diabetes Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 120. Middle East and Africa Obesity-Diabetes Drug Sales Forecast by Country (2026-2035) & (Units)
Table 121. Middle East and Africa Obesity-Diabetes Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 122. Global Obesity-Diabetes Drug Sales Forecast by Type (2026-2035) & (K MT)
Table 123. Global Obesity-Diabetes Drug Market Size Forecast by Type (2026-2035) & (M USD)
Table 124. Global Obesity-Diabetes Drug Price Forecast by Type (2026-2035) & (USD/KG)
Table 125. Global Obesity-Diabetes Drug Sales (K MT) Forecast by Application (2026-2035)
Table 126. Global Obesity-Diabetes Drug Market Size Forecast by Application (2026-2035) & (M USD)

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Obesity-Diabetes Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Obesity-Diabetes Drug Market Size (M USD), 2025-2035
Figure 5. Global Obesity-Diabetes Drug Market Size (M USD) (2020-2035)
Figure 6. Global Obesity-Diabetes Drug Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Obesity-Diabetes Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Obesity-Diabetes Drug Product Life Cycle
Figure 13. Obesity-Diabetes Drug Sales Share by Manufacturers in 2025
Figure 14. Global Obesity-Diabetes Drug Revenue Share by Manufacturers in 2025
Figure 15. Obesity-Diabetes Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Obesity-Diabetes Drug Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Obesity-Diabetes Drug Revenue in 2025
Figure 18. Industry Chain Map of Obesity-Diabetes Drug
Figure 19. Global Obesity-Diabetes Drug Market PEST Analysis
Figure 20. Global Obesity-Diabetes Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - Imports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Obesity-Diabetes Drug Market Share by Type
Figure 27. Sales Market Share of Obesity-Diabetes Drug by Type (2020-2025)
Figure 28. Sales Market Share of Obesity-Diabetes Drug by Type in 2025
Figure 29. Market Share of Obesity-Diabetes Drug by Type (2020-2025)
Figure 30. Market Share of Obesity-Diabetes Drug by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Obesity-Diabetes Drug Market Share by Application

+357 96 030922
info@marketpublishers.com

Figure 33. Global Obesity-Diabetes Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Obesity-Diabetes Drug Sales Market Share by Application in 2025
Figure 35. Global Obesity-Diabetes Drug Market Share by Application (2020-2025)
Figure 36. Global Obesity-Diabetes Drug Market Share by Application in 2025
Figure 37. Global Obesity-Diabetes Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Obesity-Diabetes Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Obesity-Diabetes Drug Market Size by Region (2020-2025)
Figure 40. North America Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Obesity-Diabetes Drug Sales Market Share by Country in 2024
Figure 43. North America Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Obesity-Diabetes Drug Market Size by Country in 2024
Figure 45. U.S. Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Obesity-Diabetes Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Obesity-Diabetes Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Obesity-Diabetes Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Obesity-Diabetes Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Obesity-Diabetes Drug Sales Market Share by Country in 2024
Figure 53. Europe Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Obesity-Diabetes Drug Market Size by Country in 2024
Figure 55. Germany Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)

+357 96 030922
info@marketpublishers.com

Figure 59. U.K. Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Obesity-Diabetes Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Obesity-Diabetes Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Obesity-Diabetes Drug Market Size by Region in 2024
Figure 68. China Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Obesity-Diabetes Drug Sales and Growth Rate (K MT)
Figure 79. South America Obesity-Diabetes Drug Sales Market Share by Country in 2024
Figure 80. South America Obesity-Diabetes Drug Market Size and Growth Rate (M USD)
Figure 81. South America Obesity-Diabetes Drug Market Size by Country in 2024
Figure 82. Brazil Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K

+357 96 030922
info@marketpublishers.com

MT)
Figure 85. Argentina Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Obesity-Diabetes Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Obesity-Diabetes Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Obesity-Diabetes Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Obesity-Diabetes Drug Market Size by Region in 2024
Figure 92. Saudi Arabia Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Obesity-Diabetes Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Obesity-Diabetes Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Obesity-Diabetes Drug Production Market Share by Region (2020-2025)
Figure 103. North America Obesity-Diabetes Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Obesity-Diabetes Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Obesity-Diabetes Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Obesity-Diabetes Drug Production (K MT) Growth Rate (2020-2025)

+357 96 030922
info@marketpublishers.com

Figure 107. Global Obesity-Diabetes Drug Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Obesity-Diabetes Drug Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Obesity-Diabetes Drug Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Obesity-Diabetes Drug Market Share Forecast by Type (2026-2035)
Figure 111. Global Obesity-Diabetes Drug Sales Forecast by Application (2026-2035)
Figure 112. Global Obesity-Diabetes Drug Market Share Forecast by Application (2026-2035)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Obesity-Diabetes Drug Market Research Report 2026(Status and Outlook)

Product link: https://marketpublishers.com/r/GD26A3AC22C9EN.html

Price: US$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GD26A3AC22C9EN.html